Showing posts sorted by relevance for query questions. Sort by date Show all posts
Showing posts sorted by relevance for query questions. Sort by date Show all posts

Tuesday, December 12, 2017

Managing the Doctor/Patient Relationship

Being one’s own patient advocate means taking responsibility for one’s own health decisions. This is a quantum change from the way things were not very long ago. My parents were very silent in their meetings with doctors. They trusted the doctor to do what was best for them, even though the doctor could only surmise, based on his subjective point of view and his experience with other patients, what it was my parents’ wanted. This is sometimes called the paternalistic model of doctor/patient relationships.

The new model places more of the responsibility with the patient. Some will not want to take that on, and that’s OK too. Sometimes it can’t be salvaged – the personalities and goals are just too different. Patients drop doctors, and vice versa. 

Shared decision-making

The new model of doctor/patient relationships calls for shared decision-making. The doctor and patient work out the treatment plan collaboratively. This puts a greater onus on the patient, and relieves the doctor of some of his traditional responsibilities. Most doctors don’t really want to play God.

The patient must make explicit to the doctor what his priorities are. He has to think about what is really important to him, and which oncological risks and risk of adverse events from treatments he is willing to take. Are you willing to trade some quantity of life for quality of life? Are you willing to forgo ADT with radiation even though it may work better with it in the hope of diminished sexual side effects? Are you willing to try chemo earlier rather than later in disease progression to get a longer survival benefit, but knowing it may eventually fail? Do you want to put off taking ADT to have better quality of life, knowing the disease may progress unchecked? How much pain are you willing to tolerate without feeling drugged all the time? These are hard choices.

Also, let the doctor know if you are willing to enter clinical trials or be treated with an experimental protocol. Some patients want the tried-and-true, and most doctors will only offer the standard-of-care unless the patient speaks up. You have to decide for yourself if the potential benefit of an experimental protocol outweighs the risk that it might not work as well.

It helps to become as informed as you can in preparation for the meeting with your doctor. Try to meet the doctor on his own terms and with his own terms. On his own terms means that the information you accumulate is of the same quality as his information – studies published in recognized peer-reviewed publications, rather than anecdotes from a co-worker or random Internet sites. With his own terms means trying to learn the lingo as best as you can. Know the meaning of "Gleason score", "stage" and "PSA," for example. At a meeting last year, a patient asked a doctor, “For how long will I need ADT if I have radiation?” The doctor explained that it depended on his risk level, which was a reasonable answer. However, I knew what the patient really meant (I talked to him earlier) and asked “He means, for how long must he be on ADT neo-adjuvantly?” By knowing the terminology, I got the answer the patient wanted.

The doctor has responsibilities under this model too. He is responsible for administering treatments that maximize oncological control while minimizing side effects of treatment within the limits dictated by the patient. The doctor becomes the key information resource for the patient. He should provide a realistic assessment of the risks and benefits attached to each treatment option. Full disclosure of all possible side effects should be discussed and provided in writing. He must listen to the patient and acknowledge the factors that are most important to him.

Because there is so much more shared information under this new model, Patient Decision Aids (PDAs) have been developed. These are in writing or online booklets that take the patient through all the risks and benefits and ask him to make decisions about what is important. The doctor and the patient then discuss the PDA as an aid to negotiating a mutually satisfactory treatment plan. But a PDA is not a substitute for a face-to-face discussion. When used instead of rather than in addition to, the results can be worse than if no PDAs were used (see this link).

Managing egos

Yes, some doctors are very full of themselves, and don’t think the patient can possibly have anything useful to say. In my experience, that is a rarity. Doctors are, for the most part, exceedingly smart and intellectually curious people. To the best of their ability, they want to do what’s best for the patient. It’s all about respect. Respect his time, his experience and his knowledge, and he is likely to return the favor. If you approach him with that attitude, ego problems are likely to disappear.

Of course, it can never hurt to let him know how much you respect him. If you have something genuinely complimentary to say, verbalize it. Let him know how much you appreciate his time and effort on your behalf. If you are gracious to him, he may be more gracious to you.

I always assume he knows at least whatever information I know. He reads full-text peer-reviewed journal articles and attends conferences. However, he may have a full patient load and may not have read about some recent finding or other. (See Research data below).

Ask questions, rather than making demands. “What is your opinion about 18 months of ADT vs 3 years?” is a better approach than “I won’t take ADT for more than 18 months!”

I hate to sound sexist, but if you can, bring your wife, or a female friend or relative along (or at least take a lesson from their communication style). They have spent a lifetime dealing with the male ego, and are just better at it. Unlike men, who are often more competitive by nature, women are more naturally collaborative. That is a much more productive interaction for the doctor/patient relationship.

Research data

Sometimes you will come across a research study online that seems perfectly relevant to your case. How should you handle it with your doctor?

The way I do it is, first of all, respectfully. I start by acknowledging that he probably has seen it. My approach is collaborative and open, rather than confrontational and closed-minded. I try to share it, preferably via email, before my visit, if one is coming up. This gives him a chance to look at it and respond to it in a more considered way. I am also careful about sources. I would never send some “miracle cure” from a random Internet site. It is always based on peer-reviewed medical evidence. I am also open to refutation: I may not have understood why that case does not apply to my case; I may not know that there are more recent findings, possibly from a higher level of evidence; or, I may have misunderstood the findings or conclusions.

During the visit

You get the most out of the doctor/patient relationship if you come to the visit prepared.

• Bring your medical records with you (e.g., PSA results over time, biopsy, prostate size, staging, pathology report, medication history). I keep all my records in a computer file for easy access and retrieval.

• Bring a written list of your questions. If you try to remember – you won’t. It’s just too stressful, and there’s too much time pressure. I like to print them out and leave space to write down the doctor’s answers.

• Take notes. It’s just too easy to miss something when you’re trying to absorb so much all at once, often with unfamiliar terminology. It’s also a good idea to record the conversation, with the doctor’s permission, and to transcribe it to a computer file later. That forces you to go over it and may help you recognize that there was something that requires clarification. However, it is tedious to listen to a long meeting, and in my experience, most patients do not review the recording. Notes are better.

• Bring someone with you. Two sets of ears are better than one, as are two sets of notes. Afterward, stop for a coffee and de-brief. Compare your notes. Did you both hear the same thing?

• Write a summary of the meeting. I email it to myself so I have a permanent record. It’s not a bad idea to email your doctor a brief thank you note, and highlight what was discussed, agreed upon or left open, and what the next steps will be.

Preparation for a meeting:

Always...: 
  • ....give the doctor a heads-up that these (whatever they are) are the topics you want to address at the next meeting- email in advance of the meeting - the more notice the better. 
  • ... email the links to a peer-reviewed journal of any topics you want to discuss 
  • ...write down your questions, leaving space to write down notes of his answers (or, let whomever you bring along write them down) - debrief with that person afterward to get concurrence that you both heard the same thing. 
  • ...let the doctor know if you are willing to risk a clinical trial.   
  • ...pump up the doctor's ego - be self-effacing (note: women are usually much better at this than men are) 

Never...:   
  • ... surprise the doctor with a question - the reaction to a surprise is always the fallback position (the Standard of Care) 
  • ... pull out an article during the meeting- there is no time for him to consider it.  
  • ... tell him about something you heard from a friend or on the Internet --that is just inviting him to dismiss it.   
  • ...ask him things he can't know - e.g., which choice is better? will it work? how long do I have? 
  • ... let your ego get in the way - it isn't important to be "right" - it's important to find the best treatment for you, even if you were mistaken about it going into the meeting. 
In other words, manage the meeting the same way you would a business meeting.

Communications

We all want to eliminate unnecessary visits, but keep the essential ones. You may have to visit the doctor for treatments, certain tests, to update the diagnosis, to change the treatment plan, or to discuss side effects and remedies. But it may not be necessary to have a visit just to check in or discuss every lab test. There should be an agreed-upon purpose or goal for each visit.

I think it’s usually a good idea for the doctor to call/fax an Rx for lab tests ahead of your visit with him. Your visit becomes more productive when you can sit down together to discuss the lab test results and any actions to be taken because of them.

Most communications with your doctor can probably be handled with a quick email. Most medical centers are moving towards email communications and away from phone communications. I hope that waiting for the doctor’s phone calls, and playing “phone tag” with him will soon be a relic of the past. Also, it avoids playing “telephone” with a string of intermediaries who put their own spin on the message. If you keep it brief and to the point, email messages can be a lot more efficient and effective. It also facilitates sending copies of studies you may want his comments on.

Multiple Doctors

When faced with the primary therapy decision, there may be a large number of doctors you meet with - one or two urosurgeons, an IMRT specialist, an SBRT specialist, one or two brachytherapy specialists, a specialist in proton therapy, a specialist in ablation therapy, an active surveillance specialist, as well as experts in special diagnostic tests. It is tempting to want one doctor to be a "quarterback" and some doctors advertise themselves as doing that. I recommend that you resist that urge - never give up your power, and rely only on doctors with specific expertise. There is no doctor who knows anything close to what experienced practitioners know (which will not prevent them from expressing opinions). Get your information directly from the experts, and assess it yourself. It can be a formidable task, so take your time. There is no rush - even men with high-risk prostate cancer did no worse if they waited 3 months between diagnosis and treatment (see this link).

Some hospitals offer a team approach - sort of like one-stop shopping. All their best experts give you their opinions. Ideally, you would want to pick your own best doctors, but if you belong to an HMO, that may not be possible. If you have to have a team approach, it is best if you meet with each team member separately. Doctors are often reluctant to contradict or disagree with one another in the same room.

Sometimes it is time to move on from one kind of specialist to another. After radiation therapy, you may want to see a urologist or a proctologist/gastroenterologist to manage symptoms. Similarly, after prostatectomy, it can be useful to see a specialist in sexual medicine. If PSA increases steadily post-prostatectomy, patients should see a radiation oncologist. If all salvage therapies have failed, that is the time to see a medical oncologist.

Managing your records

Good recordkeeping is essential to good communication with your doctor. Communications are so much easier when you don’t have to guess what some report said, but can look at the actual report instead and agree on the facts.

Keep copies of all lab tests and reports. Computerize the results if you can for easier access and organization. If it’s too much trouble to enter lab test results on spreadsheets, at least scan them into your computer. To that end, I ask my doctor’s office to email me copies of all reports. With the new hospital and lab report email systems, it’s already online for me. I like to send myself copies anyway, in case I someday lose access to those systems.

I like to keep a log of all my doctor visits – just the date, the doctor, and some brief notes about what was discussed. It is handy for billing, as well as tracking the history of the disease.

There’s one chart that I find invaluable, and it's one that doctors love. That’s a chart of my PSA over time, on which I also note key events like biopsies and therapies. 

Assessment Questionnaires

It is equally important that the doctor evaluates and tracks the patient’s subjective symptoms in addition to his objective symptoms. Another series of records I like to keep is my qualitative assessment of my condition over time. 

A popular instrument for tracking quality of life with prostate cancer is called the Expanded Prostate Index Composite (EPIC). It’s a validated questionnaire used to obtain the patient’s subjective assessment of his quality of life based on urinary, rectal and sexual dimensions. Many doctors will ask you to fill it out before treatment begins to get a baseline measure. Then you fill it out periodically to track your progress on those dimensions. My RO uses it as a springboard for discussion at each visit. You can download a copy here and take it, score it (scoring instructions here), and track it over time, even if your doctor doesn’t. It might lead you to want to discuss some aspect of it with him. Another version is called the UCLA Prostate Cancer Index (UCLA-PCI). Other tests sometimes used are the International Prostate Symptom Score (IPSS) which only tracks urinary symptoms. An instrument for measuring sexual function is the International Index of Erectile Function (IIEF)  or the shortened version called the Sexual Health Inventory for Men (SHIM)

For cancer patients, the performance status is often tracked using the Karnofsky Performance Status Scale or the ECOG Performance Status. There is a questionnaire, often used in Europe, for tracking the patient’s quality of life with cancer called  EORTC QLQ-C30

Your doctor will probably also fill out a co-morbidity evaluation. The Charleson Co-Morbidity Index or the Adult Co-Morbidity Evaluation- 27 (ACE-27).

See also:

Monday, August 29, 2016

How long is long enough? Length of follow-up on clinical trials for primary treatments

Many of us are faced with the difficulty of choosing a primary therapy based on data from clinical trials with follow-up shorter than our life expectancy. How can we know what to expect in 20 or 30 years? This is quite apart from the fact that most published studies only tell us how the treatment worked for a chosen group of patients treated by some of the top doctors at some of the top institutions – they never predict for the individual case that we really want to know about; i.e., “me.” The issue of length of follow-up is particularly problematic for radiation therapies, although it may be too short for surgery and active surveillance studies as well. How can we make a reasonable decision given the uncertainty of future predictions?

I may have missed some studies, but the longest follow-up studies I have seen for each primary therapy treatment type are as follows:

• HDR brachy monotherapy - 10 years (
CET/Demanes)
• HDR brachy+EBRT - 15 years (
Kiel, Germany)
• IMRT - 10 years (
MSKCC)
• LDR brachy monotherapy - 12 years (
UWSeattle & Mt. Sinai)*
• LDR brachy+EBRT - 25 years (
RCOG)
• Protons- 10 years (
Loma Linda)
• SBRT - 9 years (
Katz)
• Robotic RP - 10 years (
Henry Ford Hospital, Detroit)
• Laparoscopic RP - 10 years (
Heilbronn, Germany)
• Open RP - 25 years (
Johns Hopkins)
• Active Surveillance - 20 years (
Toronto)

*Mt. Sinai published a study with longer follow-up (15 years); however, all patients were treated from 1988 to 1992, before modern methods were used, and such results are irrelevant (see below) for decision-making today.

On a personal note, I was treated at the age of 57 and had an average life expectancy of 24 years, possibly more because I have a healthy lifestyle and no comorbidities. So there were no data that could help me predict my likelihood of cause-specific survival and quality of life out to the end of my reasonably expected days. What's more, the therapies with the longest follow-up (open RP, brachy boost) also have the highest rates of serious side effects. With my low-risk cancer, there seemed little need to take that risk with my quality of life.

While we may be tempted to wait for longer follow-up, (1) we don't always have that luxury, and (2) there very likely will not
 be any longer follow-up. Not only is follow-up expensive, there are also the problems of non-response, drop-outs, and death from other causes. The median age of patients in radiation trials is typically around 70, so many will leave the study. The 10-yr Demanes study, for example, started with 448 patients, but there were only 75 patients with 10 years of follow-up. The “10-year” study of IMRT at MSKCC started with 170 patients, but only 8 patients were included for the full ten years! After the sample size gets this small, we question the validity of the probability estimates, and there is no statistical validity in tracking further changes. (It is worth noting that IMRT became the standard of care without longer term or comparative evidence.)

An even bigger problem is what I call
 irrelevance. Technological and medical science advances continue at so brisk a pace that the treatment techniques ten years from now are not likely to resemble anything currently available (another argument for active surveillance, if that's an option). Dose escalation, hypofractionation, IGRT technology, intra-operative planning, VMAT, variable multi-leaf collimators, on-board cone-beam CT, and high precision linacs - all innovations that have mostly become available in the last 15 years - have dramatically changed the outcomes of every kind of radiation therapy, and made them totally incomparable to the earlier versions. Imagine shopping for a new MacBook based on the performance data of the 2000 clamshell iBook. By the time we get the long-term results, they are irrelevant to the decision now at hand.

What we want to learn from long-term clinical trials are the answer to two questions: (1) Will this treatment allow me to live out my full life? and (2) what are the side effects likely to be? To answer the first question, researchers look at prostate cancer-specific survival. It’s not an easy thing to measure accurately – cause of death may or may not be directly related to the prostate cancer. We usually look at overall survival as well. For a newly diagnosed intermediate risk man, prostate cancer survival is often more than 20 years, so we can’t wait until we have those results to make a decision. Taking one step back, we look at metastasis-free survival, but that is often over 15 years. Sometimes there is clinical evidence of a recurrence before a metastasis is detected (e.g., from a biopsy or imaging). More often, the only timely clue of recurrence is biochemical – a rise in PSA over some arbitrary point. That point is set by consensus. Researchers arrived at the consensus after weighing a number of factors, especially its correlation with clinically-detected progression. Biochemical recurrence-tree survival (bRFS), or its inverse, biochemical failure (BF), is the most commonly used surrogate endpoint.

We might be comfortable if outcomes seem to have reached a plateau. For some of the above studies, we are able to look at some of the earlier reported biochemical failure rates compared to those measures reported at the end of the study (ideally broken out by risk group).
  • ·      In the Demanes Study, the 10-year results are virtually unchanged from the 8-year results.
  • ·      In the Kiel study of HDR brachy boost, the 5-, 10- and 15-year BF was 22%, 31%, and 36%.
  • ·      In the RCOG study of LDR brachy boost, the 10-, 15-, 20- and 25-year BF was 25%, 27%, 27%, and 27%
  • ·      In the Mt. Sinai study of LDR brachy, the 8- and 12-yr BF was 12% and 10% for low risk; 19% and 16% for intermediate risk; 35% and 36% for high-risk patients.
  • ·      In the MSKCC study of IMRT, the 3-, 8- and 10-yr BF was 8%, 11%, and 19% for low risk; 14%, 22% and 22% for intermediate risk; 19%, 33% and 38% for high risk patients.
  • ·      In the Katz SBRT study, the 5- and 7-year BF was 2% and 4% for low-risk, 9% and 11% for intermediate-risk, and 26% and 32% for high-risk patients.
  • ·      For comparison, the 5- 10- 15- and 25- year recurrence rates for prostatectomy at Johns Hopkins were 16%, 26%, 34% and 32%.

For most of the therapies, HDR & LDR brachy monotherapy, LDR brachy boost therapy, and SBRT, the failure rates remained remarkably consistent over the years. However, for surgery and IMRT, failure rates increased markedly in later years. Most of us can’t wait 25 or more years to see if a therapeutic option remains consistent or not, and for radiation, the results would almost assuredly be irrelevant anyway.

Ralph Waldo Emerson is misquoted as saying, “Build a better mousetrap, and the world will beat a path to your door.” An important criterion for decision-making when there is only limited data is our answer to the question: Is this a better mousetrap? Arguably, robotic surgery was only an improvement over open surgery, and not an entirely new therapy requiring separate evaluation. It has never been tested in a randomized comparison, and I doubt we will ever know for sure. Arguably, IMRT was simply a “better mousetrap” version of the 3DCRT technique it largely superseded and didn’t need a randomized comparison to prove its worth. Was HDRBT monotherapy just an improvement over HDRBT+EBRT? Was SBRT just an improvement over IMRT, or should we view it as a variation on HDRBT, which it radiologically resembles by design? There are no easy answers to any of these questions. However, as a cautionary note, I should mention that proton therapy was touted as more precise because of the “Bragg peak effect,” yet in practice seems to be no better in cancer control or toxicity than IMRT.

There is also the problem of separating the effect of the therapy from the effect of the learning curve of the treating physician. Outcomes are always better for patients with more practiced physicians. The learning curve has been documented for open and robotic surgery, but less well documented for radiation therapies. Patients treated early (and perhaps less skillfully) in a trial are over-represented in the latest follow-up, and there may be very little follow-up time on the most recently (and perhaps more skillfully) treated patients.

So when do we have enough data to make a decision? That comfort level will vary among individuals. I was comfortable with 3-year data based on choosing a theoretically “better mousetrap”, and many brave souls (thank God for them!) are comfortable with clinical trials of innovative therapies. In the end, everyone must assess for himself how long is long enough. For doctors offering competing therapies and for some insurance companies, there never seems to be long enough follow-up. I suggest that patients who are frustrated by those doctors and insurance companies challenge them to come up with concrete answers to the following questions:
  • ·      What length of follow-up do you want to see, and why that length?
  • ·      What length of follow-up was used to determine the standard of care?
  • ·      Do you need to see prostate-cancer specific survival, or are you comfortable with an earlier surrogate endpoint?
  • ·      What is the likelihood of seeing longer term results, and will there be any statistical validity to them if we get them?
  • ·      Have outcomes reached a plateau already?
  • ·      What evidence is there that toxicity outcomes change markedly after 2 years?
  • ·      Will the results still be relevant if we wait for longer follow-up?
  • ·      Is the therapy just a “better mousetrap” version of a standard of care?
  • ·      Are my results likely to be better now that there are experienced practitioners?

Monday, December 4, 2017

Questions to ask on a first visit for primary radiation therapy (IGRT/IMRT)

IGRT/IMRT Questions for Doctors
  1. How many have you planned? 
  2. How has your practice of IMRT changed over the years? 
  3. What is your 5-yr freedom from recurrence rate for patients at my risk level? 
  4. What proportion of your recurrences were local? (see this link) 
  5. What kind of urinary and rectal reactions can I expect? 
    • How long can I expect them to last? 
    • What medications or interventions do you typically give for that? 
    • Should I expect those symptoms to recur later? 
  6. What is your rate of serious (Grade 3) adverse events? 
  7. Do you see urinary strictures? 
  8. Urinary retention requiring catheterization? Fistulas? 
  9. Rectal bleeding requiring argon plasma or other interventions? 
  10. What is the margin you will treat around the prostate? 
    • Is it less on the rectal side? 
  11. Will you include the pelvic lymph nodes? 
  12. What about the seminal vesicles -proximal or entire? 
  13. What are the prescribed doses to the planned target volumes? 
  14. If applicable, in light of my unfavorable risk cancer: 
    • do you think I need a brachytherapy boost to the prostate? (see this link
    • do you think I need hormone therapy? For what duration?
  15. In light of the 8 major randomized clinical trials on hypofractionation reported in the last year (see this link), do you recommend hypofractionation (fewer treatments) for me? 
  16. Does your hospital do SBRT monotherapy for patients like me? Why not? 
  17. Do you work off a fused MRI/CT scan for the plan? 
  18. What machine do you use? (any brand of VMAT or Tomotherapy are good) 
  19. Do you use fiducials or Calypso transponders? 
    • Do you do transperineal placement of them? 
  20. What system do you use for inter-fractional tracking? (cone beam CT or stereoscopic X-ray, probably) 
  21. Is the alignment automated? 
  22. In my treatment plan, what do you identify as “organs at risk” and what dose constraints do you put on them? 
    • What dose will my penile bulb receive? 
  23. Do you use angiography to locate and spare the pudendal artery? (see this link
  24. How long does each treatment take? 
  25. How will I be immobilized during each treatment? 
  26. Are there any bowel prep or dietary requirements? 
  27. Should I avoid taking antioxidant supplements during treatment? 
  28. In your practice, among men who were fully potent, what percent remained fully potent 3-5 years later? 
  29. Have any men retained some ability to produce semen? 
  30. What is your opinion of taking Viagra preventatively? (see this link) 
  31. Do you monitor side effects with the EPIC questionnaire? 
  32. In your practice, what percent of men experience acute urinary side effects? 
  33. In your practice, what percent of men experience acute rectal side effects? 
  34. In your practice, what percent of men experience late term urinary side effects? 
  35. In your practice, what percent of men experience late term rectal side effects? 
  36. What kind of PSA pattern should I expect following treatment? 
  37. What is the median PSA nadir you are seeing in your practice, and how long does it take to reach that, on the average?
  38. If there should be a biochemical (PSA) recurrence, what would the next steps be? (they have to prove it’s local but not distant) 
  39. Have you ever used SBRT, brachy, or cryo for salvage after a local IMRT failure, and was that focal or whole gland? 
  40. Are you open to email communications between us?

Thursday, August 31, 2017

The myth that younger men should not pursue active surveillance

In spite of no evidence to back up their assertion, I continue to hear urologists say things like "If you were older, I'd recommend active surveillance. But because you're young, you should have surgery for your low risk prostate cancer now while your recovery will be better." We saw, in a previous article, that immediate surgery rather than active surveillance only resulted in more years of expected misery from impotence and incontinence: see: "Can a man be too young for active surveillance?"

Now, a new study from Memorial Sloan Kettering Cancer Center examines the evidence for potency preservation. The authors, who include John Mulhall, the sexual medicine specialist, demonstrate that the expected loss of erectile function is never compensated for by better recovery in younger men and the age-related decline in erectile function over the years while waiting on active surveillance.

They used a standard questionnaire, the International Index of Erectile Function 6 (IIEF6). It is sometimes called the Sexual Health Inventory for men (SHIM). There are six questions, and the best score (excellent erectile function) is 30. The questions are:

1. Over the last month, how often were you able to get an erection during sexual activity?
2. Over the last month, when you had erections with sexual stimulation, how often were your erections hard enough for penetration?
3. Over the last month, when you attempted intercourse, how often were you able to penetrate your partner?
4. Over the last month, during sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?
5. Over the last month, during sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?
15. Over the last month, how do you rate your confidence that you can get and keep your erection?

All men filled out the questionnaire before surgery and periodically for two years. They excluded high risk patients who wouldn't be eligible for active surveillance, and any men who did not have bilateral nerve-sparing surgery. Men who had hormone therapy or salvage radiation were also excluded. There were 1,103 men in their cohort of men treated with RP at MSKCC between 2009-2013. Needless to say, MSKCC has some of the best, most experienced surgeons in the world.

They first looked at the baseline scores by age to get an understanding of how erectile function declines with age. This defines the expected erectile function if there were no surgery. They also looked at actual scores after surgery for each age. The difference between actual and expected shows the true effect of surgery on erectile function, with compensation for age-related decline and for the time delay caused by active surveillance.

They found that:

  • Each year increase in age reduced the IIEF6 score by -0.27
  • Erectile function recovery after RP declined by -0.16 for each year older at the age of treatment

While younger men started with a higher erectile function score, and their recovery after RP was better, it was never good enough to be better than the erectile function of an older man who didn't have surgery. At all time points, they would have been better off if they had delayed treatment and stayed on active surveillance. There was no "window of opportunity" where younger age recovery exceeded what would be expected to happen if they waited.

The authors conclude:
Small differences in erectile function recovery in younger men are offset by a longer period of time living with decreased postoperative function. Better erectile recovery in younger men should not be a factor used to recommend immediate surgery in patients suitable for active surveillance, even if crossover to surgery is predicted within a short period of time.

I hope patients whose urologists spout the myth that "early surgery will lead to better long-term erectile function than delaying until he is older" will email this important study to them and ask for comment.

Monday, December 4, 2017

Questions for an adjuvant or salvage radiation doctor

Questions for a Adjuvant or Salvage Radiation Interview.

1. How many prostate cancer patients have you treated with adjuvant/salvage radiation?

2. How has your practice of salvage treatment changed, if at all?

3. Is there any kind of scan that you recommend to rule out metastases that might be useful at my current PSA?

4. What is the probability that I need salvage treatment? Do you calculate that from a nomogram?

5. Do you think I should get a Decipher test to find my probability of metastasis in the next 5/10 years? Do you know if my insurance covers it? What do you think about their PORTOS score?

6. How large a dose do you propose for the prostate bed? (should be near 70 Gy -72 Gy)

7. Do I need pre-treatment, concurrent or adjuvant ADT?

     a. Why?

     b. What's the evidence that it's useful?

     c. For how long?

8.How do you decide whether to treat the pelvic lymph nodes?

     a. If so, at what dose?

     b. How do you plan to prevent bowel toxicity?

     c. How will you account for the separate movement of that area and the prostate bed?

9. What do you think of doing this in fewer treatments (hypofractionation)?

10. What kind of machine do you use? (e.g., RapidArc, Tomotherapy, etc.) Why do you prefer that one?

11. What is the actual treatment time for each treatment? (faster is better)

12. What kind of image guidance do you propose? fiducials in the prostate bed? Using the fixed bones only? Soft tissue?

13. How will inter- and intra-fractional motion be compensated for?

14. What measures do you propose to spare the bladder and rectum?​ (ask about treatment margins and dose constraints)

15. What side effects can I reasonably expect, and how do we handle them?​(discuss in detail!)

16. What probability of a cure can I reasonably expect, given my stats? Is there a nomogram you use to come up with that?

17. How will we monitor my progress afterwards, both oncological and quality of life?

18.What's the best way for us to communicate if I have a question or issue?

Questions to ask a low dose rate (seeds) brachytherapist

Questions for LDR brachytherapists

1.     How many have you performed?

2.     How has your practice of brachytherapy changed over the years?

3.     What is your 5-yr freedom from recurrence rate for patients at my risk level? What proportion of your recurrences were local?

4.     What kind of urinary and rectal reactions can I expect? How long can I expect them to last? What medications or interventions do you typically give for that? Should I expect those symptoms to recur later?

5.     What is your rate of serious (Grade 3) adverse events? Do you see urinary strictures? Urinary retention requiring catheterization? Fistulas? Rectal bleeding requiring argon plasma or other interventions?

6.     For how long should I refrain from sex with a partner?

7.     For how long should I refrain from close contact with people and pets?

8.     Among men who are previously potent, what percent of your patients return to baseline?

9.     Do you recommend ED meds as protective?

10. What kind of dose with which isotope do you use? Would adjuvant IMRT be given with that? Would hormone therapy be given with that?

11. How do you prevent seed migration?

12. Do you use “intra-operative planning” or some other technique to guide placement and assure adequate seed distribution? Do you use a template with ultrasound guidance, cone-beam CT or some other method?

13. What do you set as dose limits for organs at risk? How do you assure that urinary sphincters, the urethra, and the rectum are spared?

14. Do you do a follow-up CT or MRI after a month?  How often do you find you have to go in again to treat cold spots?

15. How will we monitor PSA? What kind of PSA pattern can I expect?

16.  What kind of aftercare (including sexual rehab) will you provide, and how will we monitor side effects, and for how long? Will you regularly monitor my urinary and erectile recovery progress with validated questionnaires like EPIC and IPSS?

17.  In your practice, what percent of men experience biochemical recurrence?
    • What % of those have been local?
    • If there should be a biochemical (PSA) recurrence, what would the next steps be?
    • Have you ever used SBRT, brachy, or cryo for salvage after a local LDR brachy failure, and was that focal or whole gland?

18.  Are you open to email communications between us?


Questions to ask a high dose rate (temporary implant) brachytherapist

HDR Brachy monotherapies doctor questions
1.        I assume we are talking about monotherapy only, without external beam radiation or hormone therapy – is that correct for my case?
2.       How many monotherapies have you performed? How many combined with external beam?
3.       How has your practice of HDR brachy changed over the years?
4.       What is your 5-yr freedom from recurrence rate for patients at my risk level? What proportion of your recurrences were local?
5.       What kind of urinary and rectal reactions can I expect? How long can I expect them to last? What medications or interventions do you typically give for that? Should I expect those symptoms to recur later?
6.       What is your rate of serious (Grade 3) adverse events? Do you see urinary strictures? Urinary retention requiring catheterization? Fistulas? Rectal bleeding requiring argon plasma or other interventions?
7.       What is the margin you will treat around the prostate? Is it less on the rectal side?
8.       What is the prescribed dose to the planned target volume?
9.       What is your treatment protocol? Number of insertions? Number of fractions? Dose per fraction? Can we vary those for convenience?
10.    What kind of imaging do you use for planning? MRI? CT? US?
11.      Do you increase dwell times in areas of known cancer?
12.    Do you use fiducials or Calypso transponders?
13.    In my treatment plan, what do you identify as “organs at risk” and what dose constraints do you put on them?
o    What dose will my penile bulb receive?
o    How do you limit urethral dose? (e.g., catheter)
14.    How long does each treatment take?
15.     How will I be immobilized/anesthetized during each treatment? What kind of analgesia is used?
16.    Are there any bowel prep or dietary requirements?
17.     Should I avoid taking antioxidant supplements?
18.    In your practice, among men who were fully potent, what percent remained fully potent 3-5 years later?
o    Have any men retained some ability to produce semen?
o    What is your opinion of taking Viagra preventatively?
19.    Do you monitor side effects with the EPIC questionnaire?
o    In your practice, what percent of men experience acute urinary side effects?
o    In your practice, what percent of men experience acute rectal side effects?
o    In your practice, what percent of men experience late term urinary side effects?
o    In your practice, what percent of men experience late term rectal side effects?
20.   What kind of PSA pattern should I expect following treatment?
21.    What is the median PSA nadir you are seeing in your practice, and how long does it take to reach that, on the average?
22.   In your practice, what percent of men experience biochemical recurrence?
o    What % of those have been local?
o    If there should be a biochemical (PSA) recurrence, what would the next steps be?
o    Have you ever used SBRT, brachy, or cryo for salvage after a local HDR brachy failure, and was that focal or whole gland?
23.   Are you open to email communications between us?